Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Challenges With ICD Leads Are Under Control, St. Jude Tells Investors

This article was originally published in The Gray Sheet

Executive Summary

The company was prepared for FDA’s recent warning letter, executives said on an earnings call. But the scrutiny is not over, analysts suggest.

You may also be interested in...

Regulatory Roundup: St. Jude Resolves Warning Letter; Classifications; IMDRF

FDA formally closed out St. Jude Medical’s warning letter that had cited deficiencies at the firm’s California defibrillator lead facility. The agency finalizes two de novo classifications. The International Medical Device Regulators Forum is set to meet in Washington, D.C., in September.

St. Jude Warning Letter Updates: CRM Facility Reinspected; Neuro Plant Awaits FDA Visit

St. Jude updated the status of its efforts to resolve FDA warnings letters linked to its cardiac rhythm management and neuromodulation divisions during its first-quarter earnings call on April 16.

St. Jude Announces CRM Approvals, Progress With Warning Letter

FDA approval of several St. Jude Medical’s new cardiac rhythm management devices, including a new defibrillator lead, suggest the agency is largely satisfied with the company’s steps to resolve a January 2013 warning letter.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts